The Breast Cancer Research Foundation

06/05/2026

Estrogen plays an important role in the body, but some breast cancers use it to grow. Factors like lifetime hormone exposure, genetics, and menopausal timing can all influence risk and treatment decisions.

From hormone therapies to newer targeted treatments, research has helped transform how estrogen-related breast cancers are treated—and BCRF-funded investigators continue to drive progress forward.

Learn more at the link in comments.

06/04/2026

Nearly one year after her breast cancer diagnosis, reflects on thrivership, community, and the importance of funding research.

At this year's Hot Pink Party (just two weeks after having a double mastectomy), Katie shared why supporting metastatic breast cancer research is so important to her—and how organizations like BCRF help bring hope to patients and families facing this disease.

Read our full interview with Katie, and what she wants you to know about breast cancer:

Katie Thurston was diagnosed with stage 4 breast cancer. Here, the Bachelorette tells BCRF the biggest surprise from her diagnosis.

06/02/2026

Research made it possible for Samantha’s breast cancer to be detected at the earliest possible stage—and continues to advance understanding of genetic risk and early detection.

After her diagnosis, Samantha joined The Pink Agenda, a partner of BCRF, to support the science driving these breakthroughs.

Research is changing what’s possible—earlier detection, improved understanding of risk, and more informed care.

Join us in advancing lifesaving research by giving today at BCRF.org/donate.

05/29/2026

1 in 10 Americans say they don’t fully trust any source for breast cancer information.

Not doctors. Not social media. Not Google. Not AI.

Our new findings reveal how Americans are navigating a breast cancer information landscape that’s more crowded—and more confusing—than ever before. From endless scrolling to conflicting advice, many people are struggling to know what’s accurate, what’s misleading, and who to trust.

We're breaking down the surprising results of our YouGov poll and what they could mean for breast cancer awareness, care, and decision-making.

Get the latest findings on where Americans are really getting breast cancer information—and why it could impact care, decisions, and outcomes at the link in comments.

05/28/2026

People diagnosed with metastatic (Stage 4) breast cancer are living longer than ever before thanks to advances in research and treatment.

A new study from BCRF investigator Dr. Jose Pablo Leone found that Stage 4 breast cancer diagnoses are rising across several breast cancer subtypes—most sharply in younger women. The findings underscore the urgent need for continued progress in prevention, early detection, and treatment innovation.

The encouraging news: Survival rates for several metastatic breast cancer subtypes have improved significantly in recent years, reflecting breakthroughs in targeted therapies, better treatment strategies, and a deeper understanding of the disease.

This is why metastatic breast cancer research remains a critical priority for BCRF-funded scientists working to improve and extend lives.

Learn more about the latest findings at the link in comments.

05/27/2026

Because of her awareness of family history, risk-informed screening, and early surveillance, Samatha was able to detect her breast cancer at the earliest stage—DCIS (stage 0). Today, she serves as Vice President of The Pink Agenda and a proud supporter of BCRF.

Her story shows how research-driven screening and early detection can change outcomes.

BCRF funds the science that helps identify risk earlier and improve care for all.

05/26/2026

Breast cancer rates among Asian American, Native Hawaiian, and Pacific Islander (AAPI) women have risen nearly 50% since 2000—yet their experiences are often overlooked.

From biological risk and dense breast tissue to culture, stigma, and survivorship, understanding breast cancer in AAPI communities requires more data and more tailored care.

Access the full BCRF AAPI webinar recording with key takeways at the link in comments.

05/22/2026

The FDA has approved Enhertu for certain people with HER2-positive early-stage breast cancer—until now, this powerful drug was used in those with metastatic disease.

EnhertuⓇ is unique because it is an antibody-drug conjugate (ADC)—the antibody helps deliver the treatment directly to HER2-expressing cancer cells, allowing it to work in a more targeted manner so that it’s effective at killing the tumors and sparing neighboring cells. This approval is based on the DESTINY-Breast11 and DESTINY-Breast05 trials and represents a major shift in the possible ways HER2-positive early breast cancer may be treated.

Learn more here: https://bit.ly/4nKvQjU

05/21/2026

Nearly half of Americans have never searched for breast cancer information—despite 1 in 8 women facing a diagnosis in their lifetime. And in a rapidly shifting information landscape, where search engines, AI tools, and social platforms are increasingly part of the health journey, trust is becoming more fragmented than ever.

Our new findings show just how complex this shift really is. From who people trust to where they turn for information to how often online content is shaping decisions about care—the digital influence on healthcare is only growing.

The takeaway isn’t to stop “doing your own research” but to redefine what good research looks like, and make sure evidence-based science is part of every step.

Read more in BCRF’s latest story on how people are really accessing health information today—and why it matters for every patient conversation: https://bit.ly/4nkkpyY

05/20/2026

Emerging research from BCRF investigator Dr. Neil Iyengar shows that metabolic health plays a key role in breast cancer outcomes, and GLP-1 therapies may support meaningful weight loss in certain groups that could benefit survivorship care.

While early data are promising, timing, safety, and long-term use must be carefully considered with an oncology care team.

Read the full interview with Dr. Iyengar at the link in comments.